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Aim To determine the role of immunoglobulin M (IgM) 
deposits in clinical manifestations, disease outcome, and 
treatment response of idiopathic and secondary focal seg-
mental glomerulosclerosis (FSGS).
Methods Kidney biopsy specimens of 171 patients diag-
nosed with FSGS (primary and secondary) and 50 control 
patients were retrospectively included in the study. For 
each patient, clinical and outcome data were obtained and 
compared to morphological parameters, including immu-
nofluorescence analysis of mesangial IgM and comple-
ment 3 (C3) deposits analyzed on kidney biopsy samples.
Results There were significant positive correlations be-
tween IgM and C3 deposition in secondary FSGS (P < 0.001) 
and between IgM and mesangial deposits detected by 
electron microscopy in secondary FSGS (P = 0.015), which 
indicated that higher IgM deposition correlated with high-
er C3 deposition and mesangial deposits only in secondary 
FSGS. Patients with secondary FSGS and the deposition of 
IgM showed inferior renal outcomes at earlier time points 
in comparison with patients with negative IgM expression 
(P = 0.022).
Conclusions We detected a positive correlation between 
IgM and C3 in secondary FSGS. The association between 
IgM deposition and worse renal outcome in secondary 
FSGS indicates that IgM may play a role in the progression 
of this disease.
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Focal segmental glomerulosclerosis (FSGS) is a clinico-
pathological syndrome that usually manifests clinically 
as nephrotic syndrome and morphologically as focal and 
segmental glomerular sclerosis under light microscopy 
(LM), a foot-process effacement under electron micros-
copy (EM), and occasional immunoglobulin M (IgM) de-
posits in immunofluorescent (IF) analysis (1-5). Both pri-
mary (idiopathic) and secondary forms of this syndrome 
have been described, with five diverse morphological 
types that occur in both clinical forms (1,6). Secondary 
FSGS has diverse etiology including gene mutations, vi-
ruses, toxins, and structural and functional adaptation, 
such as hypertrophy, hyperfiltration, and loss of renal 
mass (7).
In addition to FSGS, mesangial deposits of IgM can be 
found in various primary and secondary renal diseases, 
such as minimal change disease, mesangioproliferative 
glomerulonephritis, hypertensive nephrosclerosis, and 
diabetic nephropathy (8-12). The presence of glomeru-
lar IgM deposits in FSGS is interpreted as passive entrap-
ment of the large IgM molecule within sclerotic areas. 
However, diffuse granular IgM deposits are also present 
in FSGS in non-sclerotic mesangial areas. Furthermore, 
IgM is frequently accompanied by C3 and C4 deposits 
(10,13,14). In comparison with sclerotic areas, mesangial 
staining for IgM and C3 in non-sclerotic segments is less 
intense (15).
Recently, the presence of IgM in non-sclerotic areas of 
glomeruli has been explained by specific natural IgM bind-
ing to neoantigens exposed in injured or stressed glom-
eruli (16). The recent experimental study using an animal 
model of glomerulosclerosis documented IgM-mediated 
activation of the complement system and its role in FSGS 
progression, a finding corroborated in human biopsies 
from patients with idiopathic FSGS (17). A large retrospec-
tive study focusing exclusively on patients with primary 
FSGS and mostly on sclerotic lesions further highlighted 
the correlation between IgM and C3 glomerular deposits 
and unfavorable therapeutic responses and worse renal 
outcomes (18).
The aim of our study was to investigate the potential 
correlation between IgM and C3 mesangial deposits in 
kidney biopsy tissue of patients with both primary and 
secondary FSGS. The hypothesis tested was that the 
presence of IgM deposits in non-sclerotic areas may 
predict disease progression in some patients irrespec-
tive of disease etiology.
METHODS
Patients
We retrospectively analyzed kidney biopsy specimens and 
clinical data from diagnostic biopsies obtained between 
2003 and 2014 at the Department of Pathology and Cytol-
ogy of Dubrava University Hospital in Zagreb, Croatia, in-
cluding kidney biopsy samples of 171 adult patients with 
biopsy-proven FSGS and 50 control subjects consisting of 
consecutive patients diagnosed with either thin glomeru-
lar basement nephropathy or without significant chang-
es on renal biopsy specimen. The diagnosis of FSGS was 
made according to the FSGS definition in the Columbia 
classification (1). Patients diagnosed with FSGS were clini-
cally divided in those with primary and those with sec-
ondary FSGS. Patients without clinical evidence for sec-
ondary FSGS, such as obesity, reflux nephropathy, positive 
family history, unilateral kidney, and hypertension, were 
considered as having primary FSGS. Of 171 FSGS patients, 
for 10 patients there were insufficient clinical data to ad-
equately classify FSGS as primary or secondary, for 2 pa-
tients there were insufficient kidney biopsy specimens 
for adequate IF analysis (no IgM and C3 deposition data), 
and for 3 patients both information was missing. Thus, the 
combined analysis of primary and secondary FSGS with IF 
parameters included 166 patients, and the divided analy-
sis of primary and secondary FSGS with IF parameters in-
cluded 156 patients.
Data collection, treatment, and outcome
For each patient included in the study, available clinical data 
before kidney biopsy were collected by reviewing the pa-
tients’ medical histories. The data collected included body 
mass index (BMI), cholesterol level, triglycerides level, plasma 
protein level, blood pressure, plasma IgM level, creatinine 
level, creatinine clearance, 24-hour proteinuria level, and se-
rum albumin level. Clinical data during treatments and fol-
low-up were collected from medical records. Comparison 
analyses were performed on available collected data.
Estimated glomerular filtration rate (eGFR) was expressed 
in mL/min/1.73 m2 and calculated according to the Chron-
ic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
formula (19).
Standard therapy for patients with primary FSGS consist-
ed of a corticosteroid with immunosuppressive agents 
including cyclophosphamide, cyclosporine A, and tacroli-
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mus and combined with renin-angiotensin-aldosterone 
system (RAAS) blockade. Patients admitted after 2012 re-
ceived treatments according to the Kidney Disease Im-
proving Global Outcomes (KDIGO) guidelines (20). Stan-
dard therapy for patients with secondary FSGS was solely 
RAAS blockade with either angiotensin-converting en-
zyme inhibitors or angiotensin receptor blockers.
For evaluation of treatment response, a complete remis-
sion was defined as proteinuria <0.3 g/24 h and stable or 
improved serum creatinine, while partial remission was de-
fined as proteinuria 0.3-3.5 g/24 h and stable or improved 
serum creatinine. Treatment failure was defined as not 
reaching the criteria of complete or partial remission.
In terms of clinical outcome, we evaluated renal progres-
sion of the disease that was defined as permanent increase 
in serum creatinine by ≥50% and/or end stage renal dis-
ease and/or need for renal replacement therapy/dialysis, 
transplant or death (composite renal outcome).
Renal histopathology
Renal biopsy was performed in all patients at the time of 
diagnosis. Renal specimens were evaluated using LM, IF, 
and EM. The material for LM was cut into serial sections. 
Each section was alternately stained with hematoxylin and 
eosin, periodic acid-Schiff, Masson’s trichrome, and Jones’ 
stain. Immunofluorescence was made on a frozen sample, 
and serial sections for direct IF were stained with antibod-
ies against IgG, IgA, IgM, C3, C1q, fibrinogen, albumin, and 
the kappa and lambda light chains (Dako, Glostrup, Den-
mark). The tissues for EM were processed using standard 
methods (fixation in McDowell’s fixative followed by 2% 
osmium tetroxide, contrasting 3% uranyl acetate, acetone 
dehydration, submersion in epoxy resin, and cutting ultra-
thin sections on a ultramicrotome) and examined using a 
JEOL 1400 (Jeol, Tokyo, Japan) electron microscope.
The histological type of FSGS, total number of glomeruli, 
number of glomeruli with global and segmental sclerosis, 
presence, quantity and distribution of IgM and C3 depos-
its, foot process effacement, degree of interstitial fibrosis 
and tubular atrophy, arteriolar hyalinosis, and arterial inti-
mal thickening were determined. The histological type of 
FSGS was defined according to the criteria established by a 
group at Columbia University (1). The degree of interstitial 
fibrosis and tubular atrophy was determined semiquanti-
tatively on a section stained with Masson’s trichrome and 
expressed as a percentage of renal cortex with interstitial 
fibrosis and tubular atrophy compared to the total area of 
cortex parenchyma. Arterial intimal thickening and arterio-
FIGuRE 1. Glomerular deposits by direct immunofluorescence microscopy (x400). A. Diffuse granular staining (++) in the glomerulus 
for immunoglobulin M. B. Diffuse granular staining (+) in the glomerulus for complement 3.
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lar hyalinosis were defined according to the Banff classifica-
tion (21). The degree of podocyte foot process effacement 
was determined using at least 10 EM photographs (magni-
fication x8000) of randomly photographed regions of the 
glomeruli and expressed as a percentage of the glomerular 
basement membrane with podocyte foot process efface-
ment compared to the total analyzed area of the glomeru-
lar basement membrane.
Polyclonal rabbit anti-human IgM/ fluorescein isothiocya-
nate (FITC) and Dako FITC-conjugated rabbit anti-human 
C3c complement antibodies (Dako) were used according 
to the manufacturer’s directions. Positivity for IgM and C3 
was determined semiquantitatively in snap-frozen sec-
tions. Only diffuse, global distribution of IgM and C3 in 
nonsclerotic areas was considered positive (Figure 1), and 
the intensity of the staining was graded as negative (0), 
weakly positive (+), moderately positive (++), and strongly 
positive (+++). Microscopic analyses were performed by 
two experienced nephropathologists.
Statistical analysis
The normality of the data distribution was assessed with 
the Kolmogorov-Smirnov test and appropriate non-para-
metric tests were used in additional analyses. Differences 
between the FSGS and control groups and between the 
primary and secondary FSGS groups were analyzed with 
a χ2 test (categorical values) and a Mann-Whitney U test 
(quantitative values). Spearman correlation coefficients 
were used to analyze associations between IgM, C3 lev-
els, and EM mesangial deposits in primary and second-
ary FSGS. Kaplan-Meier survival curves were used to study 
prognostic relevance, and corresponding log-rank (Mantel-
Cox) test of equality for survival distributions was used to 
analyze different levels of IgM and C3 in primary and sec-
ondary FSGS over time for renal outcomes and response to 
treatment. Binary logistic regression was performed to an-
alyze the impact of the number of different predictors on 
the likelihood of disease progression or complete or partial 
remission. Results were expressed as odds ratios (OR) with 
TABLE 1. Differences in characteristics between patients in the control group and combined focal segmental glomerulosclerosis 
group*
No. (%) of patients
Characteristic control group (n = 50) FSGS group (n = 171) P
IgM  0.002†
negative  35 (70.0)  74 (44.6)
positive  15 (30.0)  92 (55.4)
C3
negative  48 (96.0) 141 (84.9)  0.038†
positive   2 (4.0)  25 (15.1)
IgM deposition
IgM-, C3  35 (70.0)  74 (44.6)  0.005†
IgM+, C3-  13 (26.0)  69 (41.6)
IgM+, C3+   2 (4.0)  23 (13.9)
Mesangial deposits by EM‡
negative  44 (88.0) 130 (82.8)  0.382†
positive   6 (12.0)  27 (17.2)
Gender
female  33 (66.0)  56 (32.7) <0.001†
male  17 (34.0) 115 (67.3)
Age (years; median, IQR)  39.0 (28.3-49.3)  50.0 (36.0-61.0) <0.001§
Blood pressure (mmHg; median, IQR)
systolic 120.0 (115.0-135.0) 145.0 (130.0-160.0)  0.006§
diastolic  77.5 (70.0-81.3)  90.0 (80.0-100.0) <0.001§
BMI (kg/m2; median, IQR)  25.5 (23.5-30.0)  28.0 (24.9-32.1) <0.001†
*Abbreviations: FSGS – focal segmental glomerulosclerosis, Ig – immunoglobulin, C – complement, EM – electron microscopy, IQR – interquartile 
range, BMI – body mass index.
†χ2 test.
‡Excluded patients without EM data for glomeruli analysis.
§Mann-Whitney U test.
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95% confidence intervals (95% CI). If the P value of the can-
didate predictor in univariate survival analysis was <0.05, 
the predictor was included in the multivariable regression 
model. All statistical analyses were two tailed, and a P value 
<0.05 was considered as statistically significant. The data 
analysis software system IBM SPSS Statistics, version 21.0 
(IBM Corporation Armonk, NY, USA), was used for statisti-
cal analysis.
RESuLTS
Demographic, clinical, and histological characteristics
Of a total of 221 patients included in the study, 50 patients 
were in the control group and 171 in the FSGS group. Male 
gender was predominant in the combined (primary and 
secondary) FSGS patient group (Table 1). Additionally, the 
patient group was significantly older and had higher sys-
tolic and diastolic blood pressure and BMI values.
A comparison between the primary and secondary FSGS 
groups showed that the secondary FSGS group had sig-
nificantly higher values of BMI, systolic blood pressure, to-
tal serum protein, albumin, serum creatinine, and number 
of globally sclerotic glomeruli (Table 2). Serum cholesterol, 
creatinine clearance, proteinuria, total number of glomer-
uli, and the number of glomeruli with segmental sclero-
sis were significantly higher in the primary FSGS group. C3 
distribution showed more prevalent expression in the sec-
ondary FSGS, podocyte foot process effacement showed 
a higher rate in primary FSGS, and arteriolar hyalinosis was 
higher in secondary FSGS (Table 3). Primary FSGS group 
had significantly higher proteinuria levels and immuno-
suppressive therapy rates.
IgM deposition in primary and secondary FSGS
The FSGS group had a significantly higher prevalence of 
positive IgM deposition and positive C3 deposition than 
the control group (Table 1). Comparison among IgM+C3+, 
IgM+C3-, and IgM-C3- showed a significantly more preva-
lent positive IgM and C3 deposits in FSGS group.
According to the correlation coefficients between IgM and 
C3 deposition with other clinical and histological variables 
in primary and secondary FSGS, there were significant pos-
itive correlations between the IgM and C3 deposition and 
between IgM and mesangial deposits on EM in the sec-
ondary FSGS group, indicating that IgM deposition is as-
sociated with C3 deposition and EM mesangial deposits 
TABLE 2. Differences between primary and secondary focal segmental glomerulosclerosis in quantitative clinical and morphological 
characteristics*
Normal Primary FSGS (n = 47) Secondary FSGS (n = 109)
Parameter value range† 25th 50th (median) 75th 25th 50th (median) 75th P‡
Age (years)  32.0  48.0  63.0  38.0  50.5  60.0 0.769
BMI (kg/m2)  22.6  26.0  29.9  25.4  30.0  33.8 0.001
Systolic blood pressure (mmHg) 120.0 132.5 160.0 140.0 150.0 160.0 0.022
Diastolic blood pressure (mmHg)  80.0  90.0 100.0  80.0  90.0 100.0 0.151
Serum cholesterol (mmol/L) <5   5.9   7.9  10.3   5.0   5.9   7.1 <0.001
Serum triglycerides (mmol/L) <1.7   1.9   2.7   3.5   1.6   2.6   3.9 0.653
Total serum proteins (g/L) 60-78  41.0  54.0  61.0  62.7  69.0  74.8 <0.001
Albumin (g/L) 41-51  16.0  24.0  32.0  34.6  39.8  43.3 <0.001
Serum creatinine (µmol/L) 64-104  78.5  95.0 174.0  93.0 130.0 201.0 0.045
Creatinine clearance (ml/min)§  60.5  90.5 109.4  42.0  70.0 101.6 0.040
Proteinuria (g/L) <0.25   3.3   9.6  12.5   1.5   2.9   5.1 <0.001
eGFR (ml/min/1.73 m2) >90  35.0  73.30  93.50  28.90  49.30  80.90 0.067
Total number of glomeruli  13.0  18.0  27.0  10.0  13.0  19.5 0.001
Number of globally sclerotic glomeruli   1.0   1.0   3.0   1.0   3.0   5.0 0.007
Number of glomeruli with segmental sclerosis   2.0   3.0   5.0   1.0   2.0   4.0 0.015
Time to response to treatment (months)   6.0  18.0  48.0   6.0  12.0  36.0 0.443
Time to combined renal outcome (months)  12.0  30.0  72.0  12.0  24.0  60.0 0.845
*Abbreviations: FSGS – focal segmental glomerulosclerosis, BMI – body mass index, eGFR –estimated glomerular filtration rate.
†Normal values of laboratory parameters at Department of Laboratory Diagnostics, Dubrava university Hospital, Zagreb.
‡Mann-Whitney U test.
§Estimate by Cockcroft-Gault formula.
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TABLE 3. Differences between primary and secondary focal segmental glomerulosclerosis in morphological and clinical categorical 
characteristics*
No. (%) of patients
Characteristics primary FSGS (n = 47) secondary FSGS (n = 109) P†
IgM deposition  0.321
negative 23 (48.9)  44 (40.4)
positive 24 (51.1)  65 (59.7)
C3 deposition
negative 44 (93.6)  88 (80.7)  0.041
positive  3 (6.4)  21 (19.3)
IgM and C3 deposition
IgM-, C3- 23 (48.9)  44 (40.4)  0.067
IgM+, C3- 22 (46.8)  45 (41.3)
IgM+, C3+  2 (4.3)  20 (18.4)
C1q deposition
negative 44 (93.6) 104 (95.4)
positive  3 (6.4)   5 (4.6)
IgA deposition
negative 44 (93.6) 103 (94.5)
positive  3 (6.4)   6 (5.5)
IgG deposition
negative 47 (100.0) 109 (100.0)
Mesangial deposits by electron microscopy‡
negative 34 (77.2)  88 (84.6)  0.283
positive 10 (22.7)  16 (15.4)
Podocyte foot processes effacement‡
podocyte foot preserved  1 (2.3)  20 (19.6) <0.001
≤25% loss  4 (9.1)  27 (26.5)
26%-50% loss  8 (18.2)  28 (27.5)
≥50% loss 31 (70.5)  27 (26.5)
FSGS type
classic 16 (34.0)  61 (56.0) <0.001
perihilar  5 (10.6)  44 (40.4)
cellular 11 (23.4)   3 (2.8)
tip 14 (29.8)   1 (0.9)
collapsing  1 (2.1)   0 (0.0)
Arterial intimal thickening
no intimal thickening 28 (59.6)  46 (42.2)  0.106
≤25% lumen constriction  6 (12.8)  15 (13.8)
26%-50% lumen constriction 10 (21.3)  26 (23.9)
≥50% lumen constriction  3 (6.4)  22 (20.2)
Arteriolar hyalinosis
without hyalinosis 29 (61.7)  28 (25.7) <0.001
nodular hyalinosis of one arteriole  5 (10.6)  14 (12.8)
nodular hyalinosis of more than one arteriole  7 (14.9)  31 (28.4)
hyalinosis in the entire circumference  6 (12.8)  36 (33.0)
Interstitial fibrosis and tubular atrophy (%)
≤5.0 18 (38.3)  22 (20.2)  0.080
6.0-25.0 16 (34.0)  40 (36.7)
25.0-50.0  8 (17.0)  34 (31.2)
≥50.0  5 (10.6)  13 (11.9)
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only in the secondary FSGS group (Table 4). There was a 
weak positivity on direct immunofluorescence for IgA in 3 
patients with primary FSGS and 6 patients with secondary 
FSGS (Table 5). Direct immunofluorescence was also weak-
ly positive for C1q in 3 patients with primary FSGS and 5 
patients with secondary FSGS (Table 5). However, there 
was no significant correlation between IgA or C1q depos-
its and IgM and C3 deposition (Tables 4 and 5).
Treatment response
Although there was no significant difference in response 
to treatment between primary and secondary FSGS (com-
plete or partial remission of the disease) when shown as a 
binary variable, the significantly higher prevalence of par-
tial remission was found in secondary FSGS (P = 0.001).
Log-rank Mantel-Cox test of equality for the survival distribu-
tions of different intensity of IgM and C3 on IF for response 
to treatment (complete and partial remission) in the primary 
and secondary FSGS groups over time showed that patients 
in the primary FSGS group with positive C3 on IF reached 
response to treatment at an earlier time point than patients 
who had negative results for C3 on IF (P = 0.018).
To determine the risk factors for response to treatment 
(complete and partial remission) among patients with sec-
ondary FSGS, we used univariate and multivariate analy-
sis. On univariate level, three significant predictors were 
found: urinary protein level, eGFR, and interstitial fibrosis 
and tubular atrophy (IFTA). In multivariate analysis, only 
lower concentration of urinary protein was found to be a 
significant predictor of disease remission (OR 0.48, 95% CI 
0.24-0.99, P = 0.048). Male gender was only significant pre-
dictor of disease remission among patients with primary 
FSGS (OR 7.78, 95% CI 1.52-39.75, P = 0.014).
Renal outcome
There were no significant differences between the pri-
mary and secondary FSGS groups in the composite re-
nal outcome (permanent increase in serum creatinine by 
≥50% or end-stage renal disease, a need for renal replace-
ment therapy, dialysis or transplantation, or death) and 
number of re-biopsies. Patients in the secondary FSGS 
group who had more IgM deposits on IF reached the 
composite renal outcome at an earlier time point than 
patients with lower or negative IgM deposition (Fig-
ure 2, P = 0.022). In univariate analysis, urinary pro-
Proteinuria (g/L)
<1  3 (6.5)  12 (11.8) <0.001
1-3.5  9 (19.6)  41 (40.2)
3.6-10 12 (26.1)  40 (39.2)
>10 22 (47.8)   9 (8.8)
Erythrocytes in urine
negative 16 (35.6)  48 (49.0)  0.134
positive 29 (64.4)  50 (51.0)
Serum IgM (g/L)
not performed 12 (26.7)  32 (32.3)  0.719
normal levels 29 (64.4)  55 (55.6)
elevated levels  1 (2.2)   5 (5.1)
decreased levels  3 (6.7)   7 (7.1)
Therapy
symptomatic 11 (24.4)  62 (60.8) <0.001
immunosuppressive 34 (75.6)  40 (39.2)
Anti-RAAS
without anti-RAAS  2 (4.4)   8 (7.8)  0.451
anti-RAAS 43 (95.6)  94 (92.2)
*Abbreviations: FSGS - focal segmental glomerulosclerosis, Ig – immunoglobulin, C – complement, RAAS – renin-angiotensin-aldosterone system.
†χ2 test.
‡Excluded patients without data for glomeruli analysis by electron microscopy.
TABLE 3.  CONTINuED. Differences between primary and secondary focal segmental glomerulosclerosis in morphological and clini-
cal categorical characteristics*
No. (%) of patients
Characteristics primary FSGS (n = 47) secondary FSGS (n = 109) P†
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tein level and eGFR were shown as risk factors with a sig-
nificant impact on the likelihood of progression of renal 
disease in patients with secondary FSGS (Table 6). When 
these predictors where analyzed in a multivariate regres-
sion model, higher levels of urinary protein increased the 
chance for progression of renal disease by 2.55 times, 
while higher eGFR lowered that chance. Female gender 
was the only significant predictor for progression of the 
renal disease among patients with primary FSGS.
DISCUSSION
Our study showed that intraglomerular IgM and C3 de-
posits were frequently detected in both primary and sec-
ondary FSGS without the correlation with other relevant 
immunofluorescence parameters. Similarly to a previous 
study (18), our results imply that the detection of intra-
glomerular IgM and C3 deposits may serve as an addition-
al diagnostic parameter for patients with faster progression 
TABLE 4. Correlation coefficients (rho) between immunoglobulin (Ig) M and complement (C) 3 deposition with other clinical vari-
ables in primary and secondary focal segmental glomerulosclerosis (FSGS)
Primary FSGS (n = 47) Secondary FSGS (n = 109)
Variable IgM C3 IgM C3
IgM deposition rho 1 0.065 1 0.372
P 0.662 <0.001
C3 deposition rho 0.065 1 0.372 1
P 0.662 <0.001
Mesangial deposits by electron microscopy rho 0.162 -0.086 0.233 0.049
P 0.276 0.566 0.015 0.613
C1q deposition rho 0.153 -0.068 -0.092 0.001
P 0.306 0.649 0.341 0.992
IgA deposition rho 0.065 -0.068 0.147 0.080
P 0.662 0.649 0.128 0.407
C3 serum rho -0.021 -0.243 -0.024 0.118
P 0.887 0.099 0.808 0.222
C4 serum rho 0.074 -0.238 -0.071 0.095
P 0.622 0.107 0.464 0.327
IgM serum rho 0.159 0.032 -0.028 -0.316
P 0.352 0.853 0.814 0.008
TABLE 5. Differences in immunoglobulin (Ig) A and complement (C) 1q deposits regarding IgM and C3 deposition in primary and 
secondary focal segmental glomerulosclerosis (FSGS)
No. (%) of patients
FSGS negative IgA positive IgA P*
Primary IgM+, C3- 20 (45.5) 2 (66.7) 0.754
IgM+, C3+  2 (4.5) 0 (0.0)
IgM-, C3- 22 (50.0) 1 (33.3)
Secondary IgM+, C3- 42 (40.8) 3 (50.0) 0.411
IgM+, C3+ 18 (17.5) 2 (33.3)
IgM-, C3- 43 (41.7) 1 (16.7)
FSGS negative C1q positive C1q
Primary IgM+, C3- 20 (45.5) 2 (66.7) 0.754
IgM+, C3+  2 (4.5) 0 (0.0)
IgM-, C3- 22 (50.0) 1 (33.3)
Secondary IgM+, C3- 43 (41.3) 2 (40.0) 0.481
IgM+, C3+ 20 (19.2) 0 (0.0)
IgM-, C3- 41 (39.4) 3 (60.0)
*χ2 test.
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of FSGS irrespective of the disease etiology. Our results fur-
ther confirm the recent studies (17,18), challenging the 
older concept that trapped IgM is only an “innocent by-
stander”. In our study, the patients with FSGS had a signifi-
cantly higher prevalence of positive IgM and C3 deposition 
than the control group. It is likely that the activation of the 
complement system may occur secondary to IgM natural 
antibody binding to neoantigens exposed upon glom-
erular stress irrespective of the nature of injurious stimu-
lus further contributing to injury progression (17). IgM is 
generally regarded as an activator of classic complement 
pathway, but recent results suggest the activation of both 
classic and alternative pathways. Therefore, it is plausible 
that IgM activates classic pathway and then amplification 
of alternative pathway can be triggered (22).
Zhang et al (18) were the first to report the clinical signifi-
cance of IgM and C3 deposition in patients with primary 
FSGS, but not in those with secondary FSGS. Also, they fo-
cused mainly on IgM and C3 deposits in sclerotic areas of 
glomeruli. We investigated the potential correlation be-
tween IgM and C3 diffuse mesangial deposits of non-scle-
rotic glomerular areas in kidney biopsy tissue of patients 
with primary and, for the first time in human pathology, 
with secondary FSGS. We found that the patients with sec-
ondary FSGS and diffuse mesangial IgM deposits had an 
earlier development of inferior renal outcomes compared 
with patients without mesangial IgM deposits. There were 
no significant correlations between the mesangial IgM de-
posits and clinical outcome in patients with primary FSGS, 
the finding that differs from the results of the study of Zhang 
et al (18). This could be explained by the small number of 
patients with primary FSGS in our study. In addition, a corre-
lation between mesangial IgM and C3 deposits on IF in the 
secondary FSGS and between mesangial deposits detected 
by EM and IgM on IF were found. The previously reported 
study revealed that patients with primary FSGS and IgM de-
TABLE 6. Risk factors for composite renal outcome (progression of the renal disease) among patients with secondary focal segmental 
glomerulosclerosis analyzed with binary logistic regression*
univariate analysis Multivariate analysis
Composite renal outcome† HR (95% CI) P OR (95% CI) P
Female gender 2.91 (0.76-11.10) 0.119
Age (years; per 1 year) 1.01 (0.97-1.05) 0.697
Urinary protein (per 1 g/24h) 2.30 (1.09-4.86) 0.029 2.55 (1.12-5.80) 0.026
eGFR (per 10 ml/min/1.73 m2) 0.97 (0.95-1.00) 0.019 0.98 (0.95-0.99) 0.031
IgM deposition: IgM- (reference)
IgM+, C3- 1.05 (0.33-3.36) 0.933
IgM+, C3+ 1.31 (0.31-5.52) 0.709
Intensity of IgM staining (per 1+) 1.46 (0.57-3.77) 0.429
Intensity of C3 staining (per 1+) 1.57 (0.68-3.64) 0.290
Mesangial deposits (per 1+) 1.36 (0.58-3.22) 0.482
Interstitial fibrosis and tubular atrophy (%) 1.47 (0.81-2.66) 0.206
Percentage of sclerosis (per 1%) 1.33 (0.11-15.94) 0.823
*Abbreviations: HR – hazard ratio, CI – confidence interval, OR – odds ratio, eGFR – estimated glomerular filtration rate, Ig – immunoglobulin, C – 
complement.
†Composite renal outcome = permanent increase in serum creatinine by ≥50% or end-stage renal disease, a need for renal replacement therapy 
(dialysis or transplantation), or death.
FIGuRE 2. Kaplan-Meier survival curve showing that patients 
with secondary focal segmental glomerulosclerosis who had 
more immunoglobulin (Ig) M deposits on immunofluores-
cence reached the composite renal outcome at an earlier time 
point than patients with lower or negative IgM deposition 
(log-rank test; P = 0.022).
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position in glomeruli presented with higher level of serum 
IgM (18). In our study, there was no significant correlation 
between IgM/C3 deposits and serum IgM/C3 levels.
There is a historical controversy about the relevance of 
glomerular IgM deposits in the progression of nephrot-
ic syndrome in pediatric and adult patients (3,23-29). In a 
recent large retrospective study, a high proportion of pa-
tients with simultaneously occurring intraglomerular IgM/
C3 deposition failed to achieve remission and had refrac-
tory nephrotic syndrome (18). Contrary to these results, our 
study showed that patients with primary FSGS with positive 
C3 on IF reached response to treatment at an earlier time 
point than did patients who had negative results for C3. Pri-
mary FSGS cohort in our study was smaller than one in pre-
viously mentioned study. We are not sure if contradiction of 
our results relies on the cohort size difference or perhaps on 
the localization of analyzed IgM and C3 deposits. While pre-
viously study investigated mainly deposits in sclerotic areas, 
we focused on diffuse mesangial deposits. That may also 
establish the basis for new speculations on the significance 
of IgM/C3 found in sclerotic vs non sclerotic areas. Given 
our data showing a faster progression in secondary FSGS 
in patients with IgM/C3 deposits, we carefully suggest that 
ongoing intraglomerular immune response uncovers pa-
tients prone to inferior outcomes irrespective of the nature 
of glomerular disease. From the clinical point of view, tar-
geting intraglomerular immune response beyond standard 
means of nephroprotection by RAAS blockade is worth 
considering for this particular group of patients. The notion 
on role of C3 in non-immune renal injury is not new. The 
classic experimental model of hypertensive injury in trans-
genic animals overexpressing human RAAS provides evi-
dence that intraglomerular findings of complement com-
ponents precede onset of proteinuria (30).
The limitations of our study are a small number of patients, 
especially those patients with primary FSGS, and retrospec-
tive design. Also, our study provides correlations and not a 
pathophysiologic proof of concept. However, we provide 
first human biopsy report in adult patients with secondary 
FSGS showing that two classical intraglomerular immuno-
flourescence parameters (IgM and C3) may contribute to 
the clarification of this very heterogeneous group of pa-
tients. Although interventions aimed at modulations of 
complement effector molecules are increasingly used in 
autoimmune renal diseases and transplantation, we be-
lieve that further analyses are necessary to draw conclu-
sions about benefits of this kind of treatment in FSGS 
therapy (31).
In conclusion, this study showed a possible role of IgM de-
position in secondary FSGS, indicating that IgM may serve 
as a novel predictor of disease progression. In our opinion, 
a further survey of the presence and possible pathogen-
ic role of IgM in glomerulonephritis should be performed. 
Prospective studies with a larger patient cohort and ther-
apy information are warranted to definitely define the role 
of IgM in patients with faster progression of FSGS.
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